Market Overview:
Sickle cell anemia, or sickle cell disease (SCD), is a hereditary condition of the red blood cells (CREDs) characterized by the abnormal production of hemoglobin. Normally, CREDs are shaped similar to discs, giving them the ability to rapidly travel through even the thinnest blood vessels. Yet, with sickle cell disease, the CREDs have a strange crescent-shaped shape resembling that of a sickle. People with sickle cell disease have an increased risk of stroke, an increased risk of coronary artery disease, and a raised risk of mortality from heart attack and stroke.
Request a Sample Copy of the Research Report: https://www.coherentmarketinsights.com/insight/request-sample/4510
Competitive Landscape:
Bristol-Myers Squibb Company, Novartis International AG, Pfizer Inc., Emmaus Life Sciences, Inc., Bluebird Bio, Global Blood Therapeutics, Inc., ADDMEDICA, Sangamo Therapeutics, Inc., Agios Pharmaceuticals, Inc., Acceleron Pharma, Inc., Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals, Inc., and Imara, Inc.
Key Market Drivers:
Growing prevalence of sickle cell disease is expected to drive growth of the North America sickle cell disease market. Sickle Cell Disease (SCD) affects around 100,000 Americans. SCD occurs among about 1 out of every 365 Black or African-American births. SCD occurs among about 1 out of every 16,300 Hispanic-American births. About 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).
Increasing R &D in the field of sickle cell disease for drug discovery is expected to foster growth of the North America sickle cell disease market. For instance, in February 2021, Novartis announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD).
Covid-19 Impact Analysis
Covid-19 pandemic has negatively impacted the production, development, and supply of medical products require for sickle cell disease medications businesses of various companies. COVID 19 pandemic has led to unprecedented lockdown across the countries of North America which has led to the shutdown of industrial establishments and disruption in supply chain of the pharmaceutical products
Key Takeaways:
The North America sickle cell disease market is expected to exhibit a CAGR of XX % over the forecast period, due to growing number of research &development activities in the region. For instance, in January 2021, University of Illinois Chicago is involved clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the DNA of patients’ blood cells.
Reasons to Purchase this Report
• Current and future of global North America Sickle Cell Disease market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Country
- Market Opportunity Map
- Report Description
- North America Sickle Cell Disease Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- Recent Product Approvals/ Launch
- Market Trends
- Key Brand Analysis
- Key Mergers, Acquisitions, Agreements & Collaboration
- Regulatory Scenario
- Epidemiology
- PEST Analysis
- North America Sickle Cell Disease Market – Impact of Coronavirus (Covid-19) Pandemic
- Economic Impact
- COVID-19 Epidemiology
- Impact on Drug Development and Clinical Trial
- North America Sickle Cell Disease Market, By Disease Type, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Sickle Cell Anemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Sickle Beta Thalassemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Sickle Hemoglobin C Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Introduction
- North America Sickle Cell Disease Market, By Drug Type, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hydroxyurea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- L-glutamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Crizanlizumab
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Pain-relievers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Voxelotor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Introduction
- North America Sickle Cell Disease Market, By Distribution Channel, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
- Introduction
- North America Sickle Cell Disease Market, By Country, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Region at Trends
- U.S.
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017–2028, (US$ million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017–2028, (US$ million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2028, (US$ Million)
- Canada
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017–2028, (US$ million)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017–2028, (US$ million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017–2028, (US$ Million)
- Introduction
- Company Market Share Analysis
-
- Company Profiles
- Novartis International AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bluebird Bio
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Global Blood Therapeutics, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Emmaus Life Sciences, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ADDMEDICA
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sangamo Therapeutics, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Acceleron Pharma, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Agios Pharmaceuticals, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Chiesi Farmaceutici S.p.A.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Vertex Pharmaceuticals, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Imara, Inc.
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis International AG
- Company Profiles
- Section
- Research Methodology
- About us
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837